Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.|
|Citation:||Immunotherapy, 2023; 15(8):593-610|
|Publisher:||Future Medicine Ltd|
|Jake R Thompson, Julia Lai-Kwon, Rachael L Morton, Alexander D Guminski, Maria Gonzalez, Victoria Atkinson, Shahneen Sandhu, Michael P Brown, Alexander M Menzies, Grant A McArthur, Serigne N Lo, Georgina V Long, Iris Bartula|
|Abstract:||Aims: To describe the health-related quality of life (HRQoL) of melanoma brain metastasis (MBM) patients throughout the first 18 weeks of ipilimumab-nivolumab or nivolumab treatment. Materials & methods: HRQoL data (European Organisation for Research and Treatment of Cancer's Core Quality of Life Questionnaire, additional Brain Neoplasm Module, and EuroQol 5-Dimension 5-Level Questionnaire) were collected as a secondary outcome of the Anti-PD1 Brain Collaboration phase II trial. Mixed linear modeling assessed changes over time, whereas the Kaplan-Meier method was used to determine median time to first deterioration. Results: Asymptomatic MBM patients treated with ipilimumab-nivolumab (n = 33) or nivolumab (n = 24) maintained baseline HRQoL. MBM patients with symptoms or leptomeningeal/progressive disease treated with nivolumab (n = 14) reported a statistically significant trend toward improvement. Conclusion: MBM patients treated with either ipilimumab-nivolumab or nivolumab did not report a significant deterioration in HRQoL within 18 weeks of treatment initiation. Clinical trial registration: NCT02374242 (ClinicalTrials.gov).|
|Rights:||Copyright status unknown|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.